Clinical Trials Browser

Phase 2 × Lymphoma × Temozolomide × Clear all

NCT07015242 2026-03-11

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Phase 2 Recruiting

Lymphoma

NCT00248534 2018-09-04

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

Phase 2 Terminated

16 enrolled 6 charts

Lymphoma

NCT02113007 2017-02-07

Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

Phase 2 Terminated

2 enrolled 6 charts

Lymphoma

NCT00098774 2016-07-06

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Phase 2 Completed

47 enrolled 9 charts

Lymphoma

NCT00503594 2012-07-30

CNSLymphoma

Phase 2 Unknown

Lymphoma

NCT00004106 2012-06-06

Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Phase 2 Terminated

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous